Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

Each arm uses its closest stored timepoint inside the window.

Cross-trial values

value

Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.

No selected arm has this endpoint inside the time window.

Show as table
ArmTrialPhasePopulationnComparatorTimepointEstimandAssessorValue

Not shown

Every selected arm is drawn.

7 of 9 arms with a reported figure. Choose arms to narrow the chart.

ArmReported safety
Vorasidenib 40 mggrade 3 or higher adverse events: 22.8%, NEJM 2023 (placebo 13.5%)grade 3 or 4 ALT increase (pooled): 9%, labelgrade 3 or 4 AST increase (pooled): 4.8%, labelpermanent discontinuation for ALT elevation: 2.9%, label
Vorasidenib Phase 1 dosesn/r
Safusidenib (AB-218, DS-1001) 250 mgn/r
Olutasidenib 150 mggrade 3 to 4 ALT increase: 12%grade 3 to 4 AST increase: 12%
Ivosidenib Phase 1 dosesn/r
IDH1-VAC (IDH1 R132H Peptide Vaccine) not stated in sourcen/r
Olaparib 300 mgn/r

A count stays a count. This page does not turn a count into a percent.

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.